AstraZeneca stock gains as UBS cuts price target but keeps Buy rating
Published on 09/16/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock (ISIN US6549022043) is trading firmer on September 16, 2026, with the London-listed shares up around 0.8 percent to roughly 12,202 GBp as investors digest a fresh UBS price target cut and a recent setback in the company’s oncology pipeline.
UBS cuts target but stays positive
According to Aktiencheck on September 16, 2026, UBS analyst Colin White lowered his 12-month price target for AstraZeneca from 17,600 GBp to 15,200 GBp, a reduction of 2,400 Pence or about 13.6 percent.
Despite the cut, UBS maintained its Buy rating, arguing that AstraZeneca’s long-term prospects remain intact even after recent clinical trial setbacks in its pipeline.Aktiencheck With the stock around 12,218 GBp in London at the time of the analysis, UBS still saw roughly 24.4 percent upside to the new 15,200 GBp target.Aktiencheck
For investors, the quantified shift in valuation is important: the lower target acknowledges higher pipeline risk yet still implies a double-digit percentage return potential from current levels, suggesting UBS views the recent share price slide as overdone rather than the start of a structural derating.Proactive Investors
Clinical setback and oncology upside
As Yahoo Finance reported on September 15, 2026, AstraZeneca’s breast cancer pill Etcamah (camizestrant) failed to meet the primary endpoint in the Phase III SERENA-4 trial, a setback for one of the company’s key oncology growth projects.
The SERENA-4 trial enrolled 1,371 patients with ER-positive, HER2-negative advanced breast cancer and tested Etcamah plus Pfizer’s Ibrance versus standard therapy, showing numerical progression-free survival improvement but not a statistically significant benefit.Yahoo Finance
AstraZeneca had previously estimated that camizestrant could eventually generate more than USD 5 billion in annual sales in the broader first-line setting, so the SERENA-4 miss trims part of the long-term revenue opportunity in oncology.Yahoo Finance However, updated data from the Phase III SERENA-6 trial in patients who develop ESR1 mutations during first-line treatment showed Etcamah cutting the risk of disease progression or death by 55 percent, with median progression-free survival of 16.8 months versus 9.2 months for standard therapy.Yahoo Finance
On the back of these SERENA-6 data, AstraZeneca secured accelerated approval in the United States in September 2026 and European Union approval in July 2026 for Etcamah in the ESR1-mutated setting.Yahoo Finance The mix of one failed expansion study and one successful mutation-driven indication explains why analysts such as UBS simultaneously trim valuation assumptions yet keep positive ratings: growth prospects have narrowed but remain sizeable.
Insider buying and broader analyst views
Support for AstraZeneca stock also comes from insider activity. According to TipRanks on September 15, 2026, non-executive chair Michel Demare purchased 2,500 ordinary shares on September 14, 2026, at about 121.21 GBP per share in London, a transaction worth roughly GBP 303,000.
The same overview notes that the most recent analyst rating on AstraZeneca’s London stock (GB:AZN) is a Hold with a 117.00 GBP price target from one house, while TipRanks’ AI-based Spark model assigns the shares a Neutral stance.TipRanks Separately, MarketBeat data show an average analyst price target around 150 GBP and an overall Moderate Buy rating based on seven analyst opinions, six of which are Buy and one Hold.MarketBeat
This combination of insider buying near 121.21 GBP, a UBS target of 15,200 GBp (equivalent to 152.00 GBP on a pence basis) and a broader consensus around 150 GBP suggests that, despite pipeline risk, the sell-side community still expects AstraZeneca shares to trade meaningfully above their mid-September 2026 levels over the medium term.
Stock performance and trading levels
Intraday on September 16, 2026, several market overviews show AstraZeneca among the gainers in London, with the stock around 12,212 GBp and up about 0.79 percent on volumes near 476,980 shares in one snapshot.Investing.com UK A separate intraday note from finanzen.ch shows the shares up 1.0 percent to 122.38 GBP at 12:28 in London trading, having opened the day at 120.98 GBP and marking a day high at 122.44 GBP.finanzen.ch
By contrast, on September 15, 2026, finanzen.ch reported the stock closing weaker at 120.24 GBP, down 1.1 percent, after trading as low as 119.22 GBP and as high as 122.36 GBP during that session.finanzen.ch The back-to-back move from a 1.1 percent decline to a 0.8–1.0 percent gain highlights how quickly sentiment can stabilize once investors see concrete analyst responses and insider conviction after a trial-related pullback.
For U.S. investors, AstraZeneca’s American depositary shares (NYSE:AZN) provide the primary listing in USD, although one Hong Kong-based market snapshot mentions a price around USD 190.58 for the U.S. ticker, likely reflecting an asynchronous or leveraged product rather than the main ADR close.ET Net In practice, investors will typically focus on the NYSE closing price in USD as the key reference level while monitoring London trading for additional liquidity and price discovery.
AstraZeneca stock at current levels
As of September 16, 2026, AstraZeneca stock on the London Stock Exchange is trading around the 122.00 GBP mark, modestly above the prior close of 120.24 GBP and still meaningfully below the UBS target of 152.00 GBP, leaving a valuation gap of roughly 24 percent that encapsulates both the risk and opportunity in the name.
AstraZeneca stock key data
- Company: AstraZeneca PLC
- ISIN: US6549022043
- Ticker: AZN
- Trading venue: NYSE (ADR), primary listing also on London Stock Exchange in GBP
- Price (as of September 16, 2026): 122.38 GBP
- Market capitalization: [value not specified] GBP (as of September 16, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: FTSE 100
